Created by potrace 1.16, written by Peter Selinger 2001-2019beatandraise.com

GILEAD SCIENCES, INC.

Statements

Exhibits

d10k.htmdex23.htmdex107.htmdex108.htmdex1090.htmdex211.htmdex231.htmdex311.htmdex312.htmdex321.htmgild-20101231.xmlR19.xmlR44.xmlR80.xmlR97.xmlR35.xmlR51.xmlR29.xmlR11.xmlR10.xmlR60.xmlR30.xmlR100.xmlR54.xmlR8.xmlR36.xmlR41.xmlR79.xmlR66.xmlR72.xmlR58.xmlR22.xmlR89.xmlR74.xmlR31.xmlR45.xmlR43.xmlR73.xmlR49.xmlR53.xmlR92.xmlR18.xmlR86.xmlR98.xmlR94.xmlR32.xmlR82.xmlR67.xmlR57.xmlR12.xmlR3.xmlR14.xmlR90.xmlR48.xmlR78.xmlR15.xmlR24.xmlR69.xmlR20.xmlR4.xmlR83.xmlR77.xmlR27.xmlR101.xmlR39.xmlR75.xmlR81.xmlR96.xmlR68.xmlR70.xmlR50.xmlR33.xmlR16.xmlR28.xmlR102.xmlR76.xmlR52.xmlR62.xmlR9.xmlR6.xmlR61.xmlR88.xmlR91.xmlR85.xmlR5.xmlR23.xmldefnref.xmlR95.xmlR84.xmlR46.xmlR21.xmlR99.xmlR87.xmlR13.xmlR34.xmlR26.xmlR93.xmlR59.xmlR64.xmlR1.xmlR2.xmlR103.xmlR37.xmlR63.xmlR56.xmlFinancial_Report.xlsR55.xmlR47.xmlR38.xmlR25.xmlR7.xmlR65.xmlR40.xmlR71.xmlR42.xmlR17.xml

Graphics

g121379g49a70.jpg
NotesSupport
aboutterms
2.2.0.25truefalse41602 - Disclosure - Segment Information (Product Sales) (Details)truefalseIn Thousandsfalse1falsefalseUSDfalsefalse1/1/2010 - 12/31/2010 USD ($) USD ($) / shares $Duration_1_1_2010_To_12_31_2010http://www.sec.gov/CIK0000882095duration2010-01-01T00:00:002010-12-31T00:00:00Unit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170Unit13Standardhttp://www.xbrl.org/2003/instancepurexbrli0Unit14Dividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0Unit1Standardhttp://www.xbrl.org/2003/instancesharesxbrli0USDUSD$2falsefalseUSDfalsefalse1/1/2009 - 12/31/2009 USD ($) USD ($) / shares $Duration_1_1_2009_To_12_31_2009http://www.sec.gov/CIK0000882095duration2009-01-01T00:00:002009-12-31T00:00:00Unit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170Unit13Standardhttp://www.xbrl.org/2003/instancepurexbrli0Unit1Standardhttp://www.xbrl.org/2003/instancesharesxbrli0Unit14Dividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0USDUSD$3falsefalseUSDfalsefalse1/1/2008 - 12/31/2008 USD ($) USD ($) / shares $Duration_1_1_2008_To_12_31_2008http://www.sec.gov/CIK0000882095duration2008-01-01T00:00:002008-12-31T00:00:00Unit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170Unit1Standardhttp://www.xbrl.org/2003/instancesharesxbrli0Unit14Dividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0Unit13Standardhttp://www.xbrl.org/2003/instancepurexbrli0USDUSD$2false0us-gaap_SalesRevenueGoodsNetus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse73899210007389921falsetruefalsefalsefalse2truefalsefalse64693110006469311falsetruefalsefalsefalse3truefalsefalse50847960005084796falsetruefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryAggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Article 5 falsefalse3false0natruenanaNo definition available.falsetruefalsefalsefalsefalsefalsefalsefalsefalsehttp://www.gilead.com/taxonomy/role/disclosuresegmentinformationproductsalesdetails1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalseUSDtruefalse{us-gaap_ProductOrServiceAxis} : Antiviral Products Atripla [Member] 1/1/2010 - 12/31/2010 USD ($) $Duration_1_1_2010_To_12_31_201023228http://www.sec.gov/CIK0000882095duration2010-01-01T00:00:002010-12-31T00:00:00falsefalseAntiviral Products Atripla [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldigild_AntiviralProductsAtriplaMemberus-gaap_ProductOrServiceAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$5falsefalseUSDtruefalse{us-gaap_ProductOrServiceAxis} : Antiviral Products Atripla [Member] 1/1/2009 - 12/31/2009 USD ($) $Duration_1_1_2009_To_12_31_200922217http://www.sec.gov/CIK0000882095duration2009-01-01T00:00:002009-12-31T00:00:00falsefalseAntiviral Products Atripla [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldigild_AntiviralProductsAtriplaMemberus-gaap_ProductOrServiceAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$6falsefalseUSDtruefalse{us-gaap_ProductOrServiceAxis} : Antiviral Products Atripla [Member] 1/1/2008 - 12/31/2008 USD ($) $Duration_1_1_2008_To_12_31_200818http://www.sec.gov/CIK0000882095duration2008-01-01T00:00:002008-12-31T00:00:00falsefalseAntiviral Products Atripla [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldigild_AntiviralProductsAtriplaMemberus-gaap_ProductOrServiceAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$OthernaNo definition available.No authoritative reference available.falsefalse4false0us-gaap_SalesRevenueGoodsNetus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse29265790002926579falsefalsefalsefalsefalse2truefalsefalse23821130002382113falsefalsefalsefalsefalse3truefalsefalse15724550001572455falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryAggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Article 5 falsefalse5false0natruenanaNo definition available.falsetruefalsefalsefalsefalsefalsefalsefalsefalsehttp://www.gilead.com/taxonomy/role/disclosuresegmentinformationproductsalesdetails1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse7falsefalseUSDtruefalse{us-gaap_ProductOrServiceAxis} : Antiviral Products Truvada [Member] 1/1/2010 - 12/31/2010 USD ($) $Duration_1_1_2010_To_12_31_201023231http://www.sec.gov/CIK0000882095duration2010-01-01T00:00:002010-12-31T00:00:00falsefalseAntiviral Products Truvada [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldigild_AntiviralProductsTruvadaMemberus-gaap_ProductOrServiceAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$8falsefalseUSDtruefalse{us-gaap_ProductOrServiceAxis} : Antiviral Products Truvada [Member] 1/1/2009 - 12/31/2009 USD ($) $Duration_1_1_2009_To_12_31_200922220http://www.sec.gov/CIK0000882095duration2009-01-01T00:00:002009-12-31T00:00:00falsefalseAntiviral Products Truvada [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldigild_AntiviralProductsTruvadaMemberus-gaap_ProductOrServiceAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$9falsefalseUSDtruefalse{us-gaap_ProductOrServiceAxis} : Antiviral Products Truvada [Member] 1/1/2008 - 12/31/2008 USD ($) $Duration_1_1_2008_To_12_31_200821http://www.sec.gov/CIK0000882095duration2008-01-01T00:00:002008-12-31T00:00:00falsefalseAntiviral Products Truvada [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldigild_AntiviralProductsTruvadaMemberus-gaap_ProductOrServiceAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$OthernaNo definition available.No authoritative reference available.falsefalse6false0us-gaap_SalesRevenueGoodsNetus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse26499080002649908falsefalsefalsefalsefalse2truefalsefalse24896820002489682falsefalsefalsefalsefalse3truefalsefalse21066870002106687falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryAggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Article 5 falsefalse7false0natruenanaNo definition available.falsetruefalsefalsefalsefalsefalsefalsefalsefalsehttp://www.gilead.com/taxonomy/role/disclosuresegmentinformationproductsalesdetails1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse10falsefalseUSDtruefalse{us-gaap_ProductOrServiceAxis} : Antiviral Products Viread [Member] 1/1/2010 - 12/31/2010 USD ($) $Duration_1_1_2010_To_12_31_201023232http://www.sec.gov/CIK0000882095duration2010-01-01T00:00:002010-12-31T00:00:00falsefalseAntiviral Products Viread [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldigild_AntiviralProductsVireadMemberus-gaap_ProductOrServiceAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$11falsefalseUSDtruefalse{us-gaap_ProductOrServiceAxis} : Antiviral Products Viread [Member] 1/1/2009 - 12/31/2009 USD ($) $Duration_1_1_2009_To_12_31_200922221http://www.sec.gov/CIK0000882095duration2009-01-01T00:00:002009-12-31T00:00:00falsefalseAntiviral Products Viread [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldigild_AntiviralProductsVireadMemberus-gaap_ProductOrServiceAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$12falsefalseUSDtruefalse{us-gaap_ProductOrServiceAxis} : Antiviral Products Viread [Member] 1/1/2008 - 12/31/2008 USD ($) $Duration_1_1_2008_To_12_31_20082222http://www.sec.gov/CIK0000882095duration2008-01-01T00:00:002008-12-31T00:00:00falsefalseAntiviral Products Viread [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldigild_AntiviralProductsVireadMemberus-gaap_ProductOrServiceAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$OthernaNo definition available.No authoritative reference available.falsefalse8false0us-gaap_SalesRevenueGoodsNetus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse732240000732240falsefalsefalsefalsefalse2truefalsefalse667510000667510falsefalsefalsefalsefalse3truefalsefalse621187000621187falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryAggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Article 5 falsefalse9false0natruenanaNo definition available.falsetruefalsefalsefalsefalsefalsefalsefalsefalsehttp://www.gilead.com/taxonomy/role/disclosuresegmentinformationproductsalesdetails1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse13falsefalseUSDtruefalse{us-gaap_ProductOrServiceAxis} : Antiviral Products Hepsera [Member] 1/1/2010 - 12/31/2010 USD ($) $Duration_1_1_2010_To_12_31_201023230http://www.sec.gov/CIK0000882095duration2010-01-01T00:00:002010-12-31T00:00:00falsefalseAntiviral Products Hepsera [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldigild_AntiviralProductsHepseraMemberus-gaap_ProductOrServiceAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$14falsefalseUSDtruefalse{us-gaap_ProductOrServiceAxis} : Antiviral Products Hepsera [Member] 1/1/2009 - 12/31/2009 USD ($) $Duration_1_1_2009_To_12_31_200922219http://www.sec.gov/CIK0000882095duration2009-01-01T00:00:002009-12-31T00:00:00falsefalseAntiviral Products Hepsera [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldigild_AntiviralProductsHepseraMemberus-gaap_ProductOrServiceAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$15falsefalseUSDtruefalse{us-gaap_ProductOrServiceAxis} : Antiviral Products Hepsera [Member] 1/1/2008 - 12/31/2008 USD ($) $Duration_1_1_2008_To_12_31_200820http://www.sec.gov/CIK0000882095duration2008-01-01T00:00:002008-12-31T00:00:00falsefalseAntiviral Products Hepsera [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldigild_AntiviralProductsHepseraMemberus-gaap_ProductOrServiceAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$OthernaNo definition available.No authoritative reference available.falsefalse10false0us-gaap_SalesRevenueGoodsNetus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse200592000200592falsefalsefalsefalsefalse2truefalsefalse271595000271595falsefalsefalsefalsefalse3truefalsefalse341023000341023falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryAggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Article 5 falsefalse11false0natruenanaNo definition available.falsetruefalsefalsefalsefalsefalsefalsefalsefalsehttp://www.gilead.com/taxonomy/role/disclosuresegmentinformationproductsalesdetails1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse16falsefalseUSDtruefalse{us-gaap_ProductOrServiceAxis} : Antiviral Products Emtriva [Member] 1/1/2010 - 12/31/2010 USD ($) $Duration_1_1_2010_To_12_31_201023229http://www.sec.gov/CIK0000882095duration2010-01-01T00:00:002010-12-31T00:00:00falsefalseAntiviral Products Emtriva [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldigild_AntiviralProductsEmtrivaMemberus-gaap_ProductOrServiceAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$17falsefalseUSDtruefalse{us-gaap_ProductOrServiceAxis} : Antiviral Products Emtriva [Member] 1/1/2009 - 12/31/2009 USD ($) $Duration_1_1_2009_To_12_31_200922218http://www.sec.gov/CIK0000882095duration2009-01-01T00:00:002009-12-31T00:00:00falsefalseAntiviral Products Emtriva [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldigild_AntiviralProductsEmtrivaMemberus-gaap_ProductOrServiceAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$18falsefalseUSDtruefalse{us-gaap_ProductOrServiceAxis} : Antiviral Products Emtriva [Member] 1/1/2008 - 12/31/2008 USD ($) $Duration_1_1_2008_To_12_31_200819http://www.sec.gov/CIK0000882095duration2008-01-01T00:00:002008-12-31T00:00:00falsefalseAntiviral Products Emtriva [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldigild_AntiviralProductsEmtrivaMemberus-gaap_ProductOrServiceAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$OthernaNo definition available.No authoritative reference available.falsefalse12false0us-gaap_SalesRevenueGoodsNetus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse2767900027679falsefalsefalsefalsefalse2truefalsefalse2797400027974falsefalsefalsefalsefalse3truefalsefalse3108000031080falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryAggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Article 5 falsefalse13false0natruenanaNo definition available.falsetruefalsefalsefalsefalsefalsefalsefalsefalsehttp://www.gilead.com/taxonomy/role/disclosuresegmentinformationproductsalesdetails1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse19falsefalseUSDtruefalse{us-gaap_ProductOrServiceAxis} : Total Antiviral Products [Member] 1/1/2010 - 12/31/2010 USD ($) $Duration_1_1_2010_To_12_31_201023236http://www.sec.gov/CIK0000882095duration2010-01-01T00:00:002010-12-31T00:00:00falsefalseTotal Antiviral Products [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldigild_TotalAntiviralProductsMemberus-gaap_ProductOrServiceAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$20falsefalseUSDtruefalse{us-gaap_ProductOrServiceAxis} : Total Antiviral Products [Member] 1/1/2009 - 12/31/2009 USD ($) $Duration_1_1_2009_To_12_31_200922225http://www.sec.gov/CIK0000882095duration2009-01-01T00:00:002009-12-31T00:00:00falsefalseTotal Antiviral Products [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldigild_TotalAntiviralProductsMemberus-gaap_ProductOrServiceAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$21falsefalseUSDtruefalse{us-gaap_ProductOrServiceAxis} : Total Antiviral Products [Member] 1/1/2008 - 12/31/2008 USD ($) $Duration_1_1_2008_To_12_31_20082225http://www.sec.gov/CIK0000882095duration2008-01-01T00:00:002008-12-31T00:00:00falsefalseTotal Antiviral Products [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldigild_TotalAntiviralProductsMemberus-gaap_ProductOrServiceAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$OthernaNo definition available.No authoritative reference available.falsefalse14false0us-gaap_SalesRevenueGoodsNetus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse65369980006536998falsefalsefalsefalsefalse2truefalsefalse58388740005838874falsefalsefalsefalsefalse3truefalsefalse46724320004672432falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryAggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Article 5 falsefalse15false0natruenanaNo definition available.falsetruefalsefalsefalsefalsefalsefalsefalsefalsehttp://www.gilead.com/taxonomy/role/disclosuresegmentinformationproductsalesdetails1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse22falsefalseUSDtruefalse{us-gaap_ProductOrServiceAxis} : AmBisome [Member] 1/1/2010 - 12/31/2010 USD ($) $Duration_1_1_2010_To_12_31_201023227http://www.sec.gov/CIK0000882095duration2010-01-01T00:00:002010-12-31T00:00:00falsefalseAmBisome [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldigild_AmbisomeMemberus-gaap_ProductOrServiceAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$23falsefalseUSDtruefalse{us-gaap_ProductOrServiceAxis} : AmBisome [Member] 1/1/2009 - 12/31/2009 USD ($) $Duration_1_1_2009_To_12_31_200922216http://www.sec.gov/CIK0000882095duration2009-01-01T00:00:002009-12-31T00:00:00falsefalseAmBisome [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldigild_AmbisomeMemberus-gaap_ProductOrServiceAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$24falsefalseUSDtruefalse{us-gaap_ProductOrServiceAxis} : AmBisome [Member] 1/1/2008 - 12/31/2008 USD ($) $Duration_1_1_2008_To_12_31_200817http://www.sec.gov/CIK0000882095duration2008-01-01T00:00:002008-12-31T00:00:00falsefalseAmBisome [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldigild_AmbisomeMemberus-gaap_ProductOrServiceAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$OthernaNo definition available.No authoritative reference available.falsefalse16false0us-gaap_SalesRevenueGoodsNetus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse305856000305856falsefalsefalsefalsefalse2truefalsefalse298597000298597falsefalsefalsefalsefalse3truefalsefalse289651000289651falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryAggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Article 5 falsefalse17false0natruenanaNo definition available.falsetruefalsefalsefalsefalsefalsefalsefalsefalsehttp://www.gilead.com/taxonomy/role/disclosuresegmentinformationproductsalesdetails1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse25falsefalseUSDtruefalse{us-gaap_ProductOrServiceAxis} : Letairis [Member] 1/1/2010 - 12/31/2010 USD ($) $Duration_1_1_2010_To_12_31_201023233http://www.sec.gov/CIK0000882095duration2010-01-01T00:00:002010-12-31T00:00:00falsefalseLetairis [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldigild_LetairisMemberus-gaap_ProductOrServiceAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$26falsefalseUSDtruefalse{us-gaap_ProductOrServiceAxis} : Letairis [Member] 1/1/2009 - 12/31/2009 USD ($) $Duration_1_1_2009_To_12_31_200922222http://www.sec.gov/CIK0000882095duration2009-01-01T00:00:002009-12-31T00:00:00falsefalseLetairis [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldigild_LetairisMemberus-gaap_ProductOrServiceAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$27falsefalseUSDtruefalse{us-gaap_ProductOrServiceAxis} : Letairis [Member] 1/1/2008 - 12/31/2008 USD ($) $Duration_1_1_2008_To_12_31_20082223http://www.sec.gov/CIK0000882095duration2008-01-01T00:00:002008-12-31T00:00:00falsefalseLetairis [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldigild_LetairisMemberus-gaap_ProductOrServiceAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$OthernaNo definition available.No authoritative reference available.falsefalse18false0us-gaap_SalesRevenueGoodsNetus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse240279000240279falsefalsefalsefalsefalse2truefalsefalse183949000183949falsefalsefalsefalsefalse3truefalsefalse112855000112855falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryAggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Article 5 falsefalse19false0natruenanaNo definition available.falsetruefalsefalsefalsefalsefalsefalsefalsefalsehttp://www.gilead.com/taxonomy/role/disclosuresegmentinformationproductsalesdetails1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse28falsefalseUSDtruefalse{us-gaap_ProductOrServiceAxis} : Ranexa [Member] 1/1/2010 - 12/31/2010 USD ($) $Duration_1_1_2010_To_12_31_201023235http://www.sec.gov/CIK0000882095duration2010-01-01T00:00:002010-12-31T00:00:00falsefalseRanexa [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldigild_RanexaMemberus-gaap_ProductOrServiceAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$29falsefalseUSDtruefalse{us-gaap_ProductOrServiceAxis} : Ranexa [Member] 1/1/2009 - 12/31/2009 USD ($) $Duration_1_1_2009_To_12_31_200922224http://www.sec.gov/CIK0000882095duration2009-01-01T00:00:002009-12-31T00:00:00falsefalseRanexa [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldigild_RanexaMemberus-gaap_ProductOrServiceAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$OthernaNo definition available.No authoritative reference available.falsefalse20false0us-gaap_SalesRevenueGoodsNetus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse239832000239832falsefalsefalsefalsefalse2truefalsefalse131062000131062falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryAggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Article 5 falsefalse21false0natruenanaNo definition available.falsetruefalsefalsefalsefalsefalsefalsefalsefalsehttp://www.gilead.com/taxonomy/role/disclosuresegmentinformationproductsalesdetails1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse30falsefalseUSDtruefalse{us-gaap_ProductOrServiceAxis} : Other Products [Member] 1/1/2010 - 12/31/2010 USD ($) $Duration_1_1_2010_To_12_31_201023234http://www.sec.gov/CIK0000882095duration2010-01-01T00:00:002010-12-31T00:00:00falsefalseOther Products [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldigild_OtherProductsMemberus-gaap_ProductOrServiceAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$31falsefalseUSDtruefalse{us-gaap_ProductOrServiceAxis} : Other Products [Member] 1/1/2009 - 12/31/2009 USD ($) $Duration_1_1_2009_To_12_31_200922223http://www.sec.gov/CIK0000882095duration2009-01-01T00:00:002009-12-31T00:00:00falsefalseOther Products [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldigild_OtherProductsMemberus-gaap_ProductOrServiceAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$32falsefalseUSDtruefalse{us-gaap_ProductOrServiceAxis} : Other Products [Member] 1/1/2008 - 12/31/2008 USD ($) $Duration_1_1_2008_To_12_31_20082224http://www.sec.gov/CIK0000882095duration2008-01-01T00:00:002008-12-31T00:00:00falsefalseOther Products [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldigild_OtherProductsMemberus-gaap_ProductOrServiceAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$OthernaNo definition available.No authoritative reference available.falsefalse22false0us-gaap_SalesRevenueGoodsNetus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse6695600066956falsetruefalsefalsefalse2truefalsefalse1682900016829falsetruefalsefalsefalse3truefalsefalse98580009858falsetruefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryAggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Article 5 falsefalse321Segment Information (Product Sales) (Details) (USD $)ThousandsUnKnownUnKnownUnKnownfalsetrue